ORAGENICS PRICES $5.25

PRICES $5.25 MILLION COMMON STOCK OFFERING

INC. (NYSE AMERICAN: OGEN) ("Oragenics" or the "Company"), a company focused on the creation of the

Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, today announced the pricing of an underwritten public

offering of 14,189,189 shares of its common stock at a price to the public of $0.37 per share. The gross proceeds to the Company

from this offering are expected to be approximately $5,250,000, before deducting underwriting discounts and commissions and other

estimated offering expenses. Oragenics has granted the underwriters a 45-day option to purchase up to an additional 2,128,378

shares of common stock to cover over-allotments, if any. The offering is expected to close on or about November 24, 2020, subject

to customary closing conditions.

Group Partners is acting as sole book-running manager for the offering.

Company intends to use the net proceeds of the offering primarily to continue funding our pre-clinical development of our SARS-CoV-2

vaccine, Terra CoV-2 and our lantibiotics program and for general corporate purposes, including research and development activities,

capital expenditures and working capital.

offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-235763) previously filed with

the U.S. Securities and Exchange Commission (the "SEC") that was declared effective by the SEC on January 13, 2020.

A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering was filed with the

SEC. Electronic copies of the preliminary prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners,

590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: prospectus@allianceg.com. Before

investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus

and the other documents that Oragenics has filed with the SEC that are incorporated by reference in such prospectus supplement

and the accompanying prospectus, which provide more information about Oragenics and such offering. The final terms of the proposed

offering will be disclosed in a final prospectus supplement to be filed with the SEC. The preliminary prospectus supplement and

accompanying prospectus is also available, and the final prospectus supplement and accompanying prospectus will be available,

on the SEC's website at http://www.sec.gov.

press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these

securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification

under the securities laws of any such state or jurisdiction.

Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further

development of effective treatments for novel antibiotics against infectious disease. The Company is dedicated to the development

and commercialization of a vaccine candidate providing specific immunity from novel coronavirus. The Terra CoV-2 immunization

leverages coronavirus spike protein research conducted by the National Institute of Health. In addition, Oragenics has an exclusive

worldwide channel collaboration with ILH Holdings, Inc. (n/k/a Eleszto Genetika, Inc.), relating to the development of novel lantibiotics.

press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of

1995, as amended, that involve significant risks and uncertainties about Oragenics, including but not limited to statements with

respect to the completion, timing, size, and use of proceeds of the proposed underwritten offering of common stock. Oragenics

may use words such as "expect," "anticipate," "project," "intend," "plan,"

"aim," "believe," "seek," "estimate," "can," "focus,"

"will," and "may" and similar expressions to identify such forward-looking statements. Among the important

factors that could cause actual results to differ materially from those indicated by such forward-looking statements are risks

relating to, among other things, whether or not Oragenics will be able to raise capital, the final terms of the underwritten offering

of common stock, market and other conditions, the satisfaction of customary closing conditions related to the underwritten offering

of common stock, Oragenics' business and financial condition, and the impact of general economic, industry or political

conditions in the United States or internationally. For additional disclosure regarding these and other risks faced by Oragenics,

see disclosures contained in Oragenics' public filings with the SEC, including the "Risk Factors" in the Company's

Annual Report on Form 10-K, as updated by our Form 8-K Report filed with the SEC on May 8, 2020, Quarterly Reports on Form 10-Q,

and prospectus for this offering. You should consider these factors in evaluating the forward-looking statements included in this

press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof,

and Oragenics undertakes no obligation to update such statements as a result of new information, except as required by law.

Sullivan, 813-286-7900